Cortical Implication in Lower Voluntary Muscle Force Production in Non-Hypoxemic COPD Patients

Francois Alexandre, Nelly Heraud, Nicolas Oliver, Alain Varray

Title: Cortical implication in lower voluntary muscle force production in non-hypoxemic COPD patients

Authors: Francois Alexandre[1,2], Nelly Heraud[2], Nicolas Oliver[2], Alain Varray[1]

[1]Movement To Health Laboratory, Euromov, University of Montpellier 1, Montpellier, France. [2]Clinique du Souffle La Vallonie, Fontalvie, Lodève, France

Corresponding author:

Francois Alexandre, Movement To Health (M2H), Euromov, University of Montpellier 1, 700 avenue du Pic Saint Loup, 34090 Montpellier, France. Phone: (+33) 434 432 632; Fax: (+33) 434 432 644; E-mail: francois.alexandre@fontalvie.fr

Abstract

Recent studies have shown that muscle alterations cannot totally explain peripheral muscle weakness in COPD. Cerebral abnormalities in COPD are well documented but have never been implicated in muscle torque production. The purpose of this study was to assess the neural correlates of quadriceps torque control in COPD patients.

Fifteen patients (FEV_1 54.1 ± 3.6 % predicted) and 15 age- and sex-matched healthy controls performed maximal (MVCs) and submaximal (SVCs) voluntary contractions at 10, 30 and 50% of the maximal voluntary torque of the knee extensors. Neural activity was quantified with changes in functional near-infrared spectroscopy oxyhemoglobin (fNIRS-HbO) over the contralateral primary motor (M1), primary somatosensory (S1), premotor (PMC) and prefrontal (PFC) cortical areas.

In parallel to the lower muscle torque, the COPD patients showed lower increase in HbO than healthy controls over the M1 ($p<0.05$), PMC ($p<0.05$) and PFC areas ($p<0.01$) during MVCs. In addition, they exhibited lower HbO changes over the M1 ($p<0.01$), S1 ($p<0.05$) and PMC ($p<0.01$) areas during SVCs at 50% of maximal torque and altered motor control characterized by higher torque fluctuations around the target.

The results show that low muscle force production is found in a context of reduced motor cortex activity, which is consistent with central nervous system involvement in COPD muscle weakness.

Keywords: Muscle Weakness, Near Infrared Spectroscopy, Neural Activity, Central Nervous System, Peripheral Muscle Dysfunction, Quadriceps Force

Introduction

Peripheral muscle dysfunction is very frequent in COPD and has major consequences. The loss of muscle force in COPD patients has become a matter of heightened concern because it implies exercise limitation [1], increased use of health care resources [2], and higher mortality [3]. The involvement of muscle atrophy in this loss was established several years ago [4]. However, several elements point to the existence of other explanatory mechanisms. For instance, a recent study reported that COPD patients exhibit a decline in muscle force even when their muscle mass is comparable to that of healthy controls [5]. In addition, the lower muscle force across GOLD stages (between GOLD I and IV) is not explained by smaller muscle cross-sectional areas [6]. Therefore, other mechanisms should be explored to enhance understanding of the pathophysiology of muscle weakness in COPD.

A decline in muscle force can be caused by alterations in the muscle and/or the nervous system [7]. Interestingly, several studies have assessed the cerebral properties in COPD patients and reported small cerebral vessel disease [8], gray matter deficits [9], white matter lesions [9, 10] and neuronal dysfunction [11]. At a more functional level, COPD patients exhibit lengthening peripheral [12] and central [13] nervous conduction times, alterations in motor cortex excitability [14], and cognitive disorders [9, 10]. In contrast, the potential repercussions over the central motor drive and muscle performance are unknown.

A few studies have evaluated muscle activation in COPD using the twitch interpolation technique [15-17], an indirect assessment of the central motor drive. However, the results were discrepant [15-17] and no definitive conclusions could be drawn. The discrepancies may be explained by the poor sensitivity of this technique at near maximal force, which makes it difficult to discriminate two populations during maximal voluntary contractions (MVCs) [18]. Thus, the question of nervous system involvement in COPD muscle weakness remains unanswered.

An alternative to circumvent the limitations of twitch interpolation could be the use of neuroimaging techniques. Force output is directly related to cortical activity as measured by functional magnetic resonance imaging (fMRI) [19] and functional near infrared spectroscopy (fNIRS) [20]. The fNIRS oxy- (HbO) and deoxy-hemoglobin (HbR) signals are strongly correlated with the blood-oxygen-level-dependent (BOLD) fMRI signal, and they are widely acknowledged to be reliable for functional cortical activity assessment in various conditions [21-23]. In addition, fNIRS has been validated for the study of neural activity in a wide range of populations, such as the elderly [23] and COPD [24], stroke [25], and obese patients [26] during various motor tasks, including MVCs [26]. Whereas fMRI restricts body movement within the enclosed chamber, fNIRS presents a high signal-to-noise ratio and relatively poor sensitivity to motion artifacts, making it the more suitable for cortical activity assessment during exercise [27, 28].

Given the numerous cerebral alterations in COPD that have never been linked with poor muscle force production, the purpose of this study was to assess the fNIRS-neural correlates of quadriceps contraction at maximal and submaximal intensity in COPD patients. We hypothesized lower activity over motor cortical areas in COPD patients than healthy controls during quadriceps contractions.

Material and Methods

Subjects

Fifteen COPD patients and 15 age- and sex-matched sedentary healthy subjects were recruited for the study. The participation criteria for the COPD patients were forced expiratory volume in the 1st second (FEV_1) between 30 and 80% of the predicted values, with no exacerbation or weight loss in the month preceding the study. No patient had taken part in a rehabilitation program in the previous 12 months. The non-inclusion criteria for the participants were an

inability to give written consent, inability to perform the experimental maneuvers, impaired visual function, use of drugs known to impair brain function, current or past alcohol abuse, and neurologic or neuromuscular disease. All participants gave written consent. Procedures were approved by the local Ethics Committee (Comité de protection des personnes Sud Est VI, number AU980) and complied with the principles of the Declaration of Helsinki for human experimentation. The study was registered at www.clinicaltrials.gov as NCT01679782.

Design

All participants underwent a medical examination, including evaluation of resting pulmonary function, body composition and clinical parameters, before taking part in the study. The protocol consisted of maximal and submaximal voluntary contractions of the knee extensors, during which cortical activity was assessed non-invasively from changes in fNIRS signals [22, 25]. The exercise protocol is presented in Figure 1. After determination of the dominant leg, the participants performed a standardized warm-up of the knee extensors by repeating 20 submaximal voluntary contractions for 2 s every 5 s. They next performed three maximal voluntary contractions (MVCs) and three submaximal voluntary contractions (SVCs) at 10, 30 and 50% of the maximal voluntary torque twice in random order. Each MVC lasted for 5 s and two successive MVCs were separated by a 2-min resting period. Each SVC lasted for 20 s and two successive SVCs were separated by a 1.5 min resting period. The random draw to determine the order of the SVCs took place immediately after the three MVCs had been performed and the target torques calculated. A last MVC was performed to ensure the absence of neuromuscular fatigue at the end of the exercise testing.

Mechanical recordings

Subjects were comfortably seated on a dedicated ergometer for knee extensor testing (Quadriergoforme, Aleo Industrie, Salome, France) with a 30° back inclination. Chair

adjustments were made to ensure that the foot, patella and coxofemoral articulation of the dominant leg were in the same axis. The knee angle was set to 110°. The pelvis and the proximal extremity of the patella were securely attached to the chair in order to minimize movements of adjacent muscles. In addition, the head was supported by a neck brace to avoid potential head motion. Torque of the knee extensors during the contractions was recorded with a strain gauge torque sensor (Captels, Saint Mathieu de Treviers, France). The acquired analog signal was converted into digital data (DA conversion) through an acquisition system (Biopac MP100, Biopac Systems, Santa Barbara, CA, USA) and instantaneously relayed to a screen to give visual feedback. During each MVC and each SVC, subjects were verbally encouraged to ensure maximal muscle torque and to maintain the force requirement, respectively. Before the SVCs, the target torque was clearly indicated to the subjects via the computer monitor and they received visual feedback of their performance during the contractions.

Cortical activity assessment

A continuous wave multichannel functional near-infrared spectroscopy (fNIRS) system (Oxymon Mark III, Artinis, the Netherlands) was used at two wavelengths in the near-infrared range (nominal wavelengths of 760 and 850 nm) to detect regional concentration changes in oxyhemoglobin (HbO) and deoxyhemoglobin (HbR) during cortical activation over cortical motor areas. fNIRS is based on neurovascular coupling: when neural activity increases, the increase in regional cerebral blood flow is ten times higher than the increase in regional oxygen consumption. Thus, as the increase in regional cerebral blood flow greatly exceeds the increase in oxygen consumption, neuronal hemodynamic concentration is closely coupled with the increase in regional cerebral blood flow, which turns into local hyperoxygenation [29] and subsequent increase in HbO with a decrease in HbR [30]. The fNIRS-measured hemoglobin is comparable to the BOLD-fMRI signal and mainly reflects changes in cortical

151 gray matter hemodynamic [22]. The fNIRS optodes were held by a cap fixated by several
152 bands surrounding the subject's head. A total of nine channels were positioned over the
153 contralateral primary motor (M1), primary somatosensory (S1), premotor (PMC) and
154 prefrontal (PFC) cortical areas in accordance with the modified EEG 10-10 system [31]
155 (Figure 2a). The source-detector spacing was set to 3.5 cm. During probe placement, Oxysoft
156 software (V6.0, Artinis, the Netherlands) allowed real time assessment of the quality of the
157 fNIRS signal for each channel based on the light source power level and the receiver gain.
158 Hemoglobin concentrations were corrected by implementing a specific differential pathlength
159 factor ($4.99 + 0.067 \times age^{0.814}$), in order to convert the concentration changes in HbO and
160 HbR to μM units [32]. The fNIRS signal was low-pass filtered (finite impulse response) using
161 a cut-off frequency of 0.7 Hz. The sampling rate was set at 10 Hz. To avoid systemic bias, we
162 also monitored the pulsed arterial oxygen saturation (SpO_2) in a restricted group of patients
163 (n=12). The oximetry probe (Weinman, Hamburg, Deutshland) was placed on the index
164 finger and the participants were asked to keep their hand motionless throughout the
165 experiment.

166 *Data analysis*

167 During MVCs, maximal quadriceps torque (Q_{MVC}) was calculated over the highest 500-ms
168 plateau of torque during the best trial of the three MVCs.

169 During SVCs, task matching was evaluated by averaging and comparing the mean performed
170 torque versus the target torque. In addition, during each SVC, the motor control was assessed
171 from the fluctuations around the target. An inaccuracy index ($Inaccuracy_{index}$) was calculated
172 and represents the RMS (root mean square) of the difference between produced and target
173 torques during the 20 s of submaximal voluntary contractions expressed as a percentage of the
174 target torque [33]. The normalization by the target torque is necessary because the torque
175 variability is known to be proportional to the torque level [34].

Changes in cortical activity were determined from HbO variations as previously described [25]. HbO signals with artifacts or a too-low signal-to-noise ratio were marked and excluded from the analyses under a visual pre-processing analysis [35]. During the best trial of the three MVCs and of the more accurate SVCs at 10, 30 and 50% of Q_{MVC}, the area under the curve of HbO normalized over time was used as an index of neural activity (Figure 2b).

The data, taken from the four channels over the M1 area, the two channels over the S1 area, and the two channels over the PMC area were averaged, resulting in the overall response of, respectively, the M1, S1 and PMC areas.

Before the beginning of exercise testing, resting HbO was calculated for each cortical area over a 2-min resting period, respecting the same analysis process as aforementioned.

Statistical analysis

All statistical analyses were performed using Statistica software (StatSoft, Inc., version 6.0, Tulsa, OK, USA). All data were examined for normality using a Shapiro-Wilk test. Differences in subject characteristics and variables recorded during MVCs were tested between controls and patients using an unpaired Student's t-test. Absence of neuromuscular fatigue was tested using a two-way analysis of variance (ANOVA) with group as between-subject factor (COPD and controls) and condition (before and after exercise testing) as within-subject factor. The $Inaccuracy_{index}$ and HbO recorded during SVCs were tested using a two-way ANOVA with group as between-subject factor and torque level (10, 30 and 50% of Q_{MVC}) as within-subject factor. Analysis of covariance (ANCOVA) with adjustment for Q_{MVC} was used to ensure that the difference in HbO between patients and controls was not due to a difference in muscle torque between the groups. Task compliance during SVCs was tested with a three-way ANOVA with group as between-subject factor and condition (target versus performed) and torque level (10, 30 and 50% of Q_{MVC}) as two within-subject factors. The underlying assumptions of ANOVA were checked using a Levene test (homogeneity of the

variance) and a Mauchly test (sphericity of the variance). When the ANOVA F ratio was significant ($p<0.05$), the means were compared by a LSD post-hoc test. Data are reported as means and standard error of the mean (SE).

Results

Subject characteristics

The subject characteristics are given in Table 1. Consistent with the matching, no difference in the gender ratio or age was observed between patients and controls. Weight, body mass index and fat-free mass index exhibited no significant differences ($p>0.05$). According to the Voorrips questionnaire [36], the level of physical activity was comparable for patients and controls ($p=0.64$).

Control of absence of desaturation and fatigue during exercise testing

SpO_2 remained stable for all patients during both MVCs and SVCs. The mean ΔSpO2 was 0.01 ± 0.12 % during MVCs ($p=0.98$) and 0.017 ± 0.19 % during SVCs ($p=0.98$).

Absence of neuromuscular fatigue was checked by changes in Q_{MVC} after the protocol. Both patients and controls exhibited no significant differences in Q_{MVC} (condition and interaction *F* ratio ranged from 0.17 to 1.10, p ranged from 0.31 to 0.68).

Maximal voluntary contractions

Q_{MVC} was significantly lower by 24.8% in COPD patients compared with controls (131.9 ± 16.6 and 175.4 ± 24.9 Nm, respectively, for patients and controls, $t=2.5$, $p<0.05$).

The regional HbO during MVCs is shown in Figure 3. Compared with controls, patients showed significantly lower HbO changes over M1 ($t=2.1$, $p<0.05$), PMC ($t=2.3$, $p<0.05$) and PFC ($t=3.1$, $p<0.01$). In contrast, HbO changes during MVCs were comparable between patients and controls over S1 ($t=0.3$, $p=0.74$).

Submaximal voluntary contractions (SVCs)

Task matching during SVCs was checked by comparing the performed torque with the target torque (Figure 4). No significant differences were found between performed and target torques for patients or controls at the three submaximal torque levels (F ranged from 0.31 to 2.22, p ranged from 0.15 to 0.74). In contrast, the $Inaccuracy_{index}$ was significantly higher in patients compared with controls for all submaximal torque levels ($F=7.99$, $p<0.001$). At 10, 30 and 50% of Q_{MVC}, the $Inaccuracy_{index}$ was 7.04 ± 0.59 vs 5.15 ± 0.62, 4.6 ± 0.44 vs 3.46 ± 0.58, and 4.83 ± 0.47 vs 3.69 ± 0.78 in patients and controls, respectively.

The regional HbO as a function of torque level is shown in Figure 5.

Over the M1 area, HbO was significantly increased compared with resting values, from 30% of Q_{MVC} in controls ($p<0.001$) and from 50% of Q_{MVC} in patients ($p<0.01$). Compared with controls, patients showed significantly lower HbO changes at 30% and 50% of Q_{MVC} (respectively, $p<0.05$ and $p<0.01$).

Over the S1 area, HbO was significantly increased compared with resting values, from 50% of Q_{MVC} in controls ($p<0.001$). In patients, HbO did not change significantly whatever the submaximal torque (p ranged from 0.34 to 0.49). In addition, at 50% of Q_{MVC}, HbO changes were significantly lower in COPD patients than in controls (0.26 ± 0.09 vs 0.59 ± 0.18 µM, $p<0.05$).

Over the PMC area, HbO was significantly increased compared with resting values, from 30% of Q_{MVC} in patients and controls (systematically $p<0.01$). Compared with controls, patients showed lower HbO changes at 50% of Q_{MVC} (0.25 ± 0.13 vs 0.72 ± 0.12 µM, $p<0.01$).

Over the PFC area, HbO was significantly increased compared with resting values, at 50% of Q_{MVC} in patients and controls (systematically $p<0.05$). There was no difference in HbO changes between patients and controls for any submaximal torque level (F ranged from 0.75 to 0.9, p ranged from 0.35 to 0.53).

The impact of the patients' lower absolute torque values compared with controls on HbO changes was checked using an ANCOVA. Consistently with respect to Figure 6 and adjusting for Q_{MVC}, HbO remained significantly lower over M1 at 30% and 50% of Q_{MVC} in patients compared with controls (all $p<0.05$). Similarly, the observed effects in HbO changes over the S1, PMC and PFC areas were unaffected when Q_{MVC} was added as a covariable: HbO changes remained significantly lower over the S1 and PMC areas in patients at 50% of Q_{MVC} (all $p<0.05$), but comparable between the patients and controls over the PFC area (F ranged from 0.01 to 2, p ranged from 0.17 to 0.99).

Discussion

The present study is the first to assess the neural correlates of quadriceps contractions in COPD patients. The main findings were lower HbO changes over the M1, PMC and PFC areas during maximal voluntary contractions in the COPD patients compared with controls. In addition, the COPD patients showed lower HbO changes than controls over the M1 area at 30% and 50% of Q_{MVC} and over the S1 and PMC areas at 50% of Q_{MVC}. Last, the COPD patients exhibited greater torque fluctuations around the target than controls.

The COPD patients exhibited 24.8% lower muscle force than healthy controls. This is consistent with the usual torque deficit reported in the literature in moderate COPD patients, which ranges from 20% to 30% [37]. The neural correlates of quadriceps torque were simultaneously recorded with the non-invasive neuroimaging fNIRS technique [22, 25] over major cortical areas for movement generation. Our results show smaller HbO increases over the M1, PMC and PFC areas in the COPD patients during MVCs. These results cannot be due to oxygen desaturation because the exercise did not induce SpO_2 changes. Similarly, it may not be explained by lower resting cerebral blood flow due to resting blood gases abnormalities because cerebrovascular reactivity to hypoxemia (increase in cerebral blood flow when PaO_2

decreases) is preserved in COPD [38, 39]. According to the neurovascular coupling principle (as previously explained in the methods section), the data thus obtained with the fNIRS technique suggest a smaller local hyperoxygenation at the cortex in COPD patients compared with healthy controls. These results support lower neural activity in these patients, which would explain the decreased voluntary torque via reduced cortical motor output, and is coherent with the cerebrovascular damage and gray matter deficit described in the literature [8,9].

During the submaximal voluntary contractions, we found a smaller HbO increase in the patients over the three main cortical areas of the frontal lobe involved in the execution and control of visual-motor tasks [40], at 30 and 50% of Q_{MVC} over the M1 area, and at 50% over the PMC and S1 areas. These results complete and support the findings of Vivodtzev et al. [17], who indirectly showed lower activation in COPD for comparable submaximal force levels with the twitch interpolation technique. In parallel to the altered neural activity, we found an increase in the inaccuracy index for submaximal torque levels in the COPD patients compared with controls, indicating greater torque fluctuations around the target in patients. Such torque fluctuations, known as dysmetria, are classic signs of lesions in the cerebellum [41], a subcortical area whose main function is the control and coordination of movement and whose output travels to motor and premotor cortex [42]. Interestingly, the dysmetria reported in the patients did not impact the task matching, as they were able to reach the required target (mean values). Hence, to summarize, the COPD patients were able to reach the desired target at submaximal intensities but with lower motor drive and high fluctuations, indicating less efficient motor control.

Given the difference in absolute torque value between the COPD patients and controls, we sought to ensure that the lower neural activity did not result from the lower muscle torque developed by the patients. As shown in Figure 6, for any given absolute torque value,

increases in HbO were always about twice lower in the patients over M1. This agrees with the analysis of covariance, which indicated that adjusting for maximal voluntary torque had no impact on the difference in HbO changes between the COPD patients and controls. Taken together, these results provide new insight into the functional limitations in COPD patients, as the lower neural activity (lower increase in HbO) cannot be explained by either lower muscle torques or a lack of patient motivation or cooperation.

"In a previous study, Higashimoto et al. [24] recorded neural activity over the PFC area during a whole-body exercise that induced an increase in dyspnea score in both COPD patients and controls during testing, with the increase being higher in COPD. The authors reported a clear tendency toward smaller HbO changes in the COPD patients compared with healthy controls, although it did not reach the significance threshold. In addition, they reported correlations between the increase in dyspnea score and the increase in PFC activity during the exercise testing. These results raised the possibility of lower neural activity during whole-body exercise in COPD that might have been hidden by the greater increase in dyspnea-induced PFC activation [24]. Our findings are consistent with and complete the results of Higashimoto et al. [24], because a local exercise carried out without any dyspnea confirmed that the COPD patients had lower cortical activity."

Several factors have been suggested to explain the cerebral alterations in COPD but the exact mechanisms remain unclear. These factors notably include inflammation, oxidative stress, hypoxemia and vascular disease [43]. In accordance with other studies [10], we report cerebral alterations in stable non-hypoxemic COPD patients, ruling out a determining role for hypoxemia. Understanding the mechanisms of the brain impairment in COPD patients has become a major issue. Our results provide new insight into the extrapulmonary effects of COPD on the brain and suggest new directions for research in order to optimize treatment for muscle force recovery in COPD. Further, they suggest the interest of early physical activity

for COPD patients, given the potential effects of exercise on cerebral plasticity and neuroprotection [44], although this has yet to be specifically investigated in COPD.

In summary, COPD patients showed lower HbO changes over cortical motor areas during maximal and submaximal voluntary contractions of the knee extensors. This impairment was associated with a decrease in the maximal voluntary torque and altered motor control. The results provide the first evidence that the knee extensors of patients with stable moderate COPD cannot be optimally driven by the brain. Our findings highlight a lower motor cortex activity during quadriceps contraction in COPD and are consistent with an involvement of the central nervous system in the COPD quadriceps torque impairment. To optimize muscle force recovery in COPD patients, interventions targeting neuroprotection and neuroplasticity must be strongly considered.

Acknowledgment

The authors would like to thank Prof. Stephane Perrey for the use of the NIRS equipment funded by a grant in aid from the Languedoc-Roussillon Region Council (AVENIR). Further, the authors wish to thanks Jean-Paul Micallef for his assistance in the development of experimental materials.

References

1. Gosselink R, Troosters T, Decramer M (1996) Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 153: 976-980.
2. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G (1997) Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 10: 417-423.
3. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, et al. (2007) Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 62: 115-120.

353 4. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, et al. (1998) Peripheral muscle
354 weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit
355 Care Med 158: 629-634.
356 5. Menon MK, Houchen L, Harrison S, Singh SJ, Morgan MD, et al. (2012) Ultrasound
357 assessment of lower limb muscle mass in response to resistance training in COPD.
358 Respir Res 13: 119.
359 6. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, et al. (2012) Quadriceps
360 wasting and physical inactivity in patients with COPD. Eur Respir J 40: 1115-1122.
361 7. Clark BC, Manini TM (2008) Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci
362 63: 829-834.
363 8. Lahousse L, Vernooij MW, Darweesh SK, Akoudad S, Loth DW, et al. (2013) Chronic
364 obstructive pulmonary disease and cerebral microbleeds. The Rotterdam Study. Am J
365 Respir Crit Care Med 188: 783-788.
366 9. Zhang H, Wang X, Lin J, Sun Y, Huang Y, et al. (2013) Reduced regional gray matter
367 volume in patients with chronic obstructive pulmonary disease: a voxel-based
368 morphometry study. AJNR Am J Neuroradiol 34: 334-339.
369 10. Dodd JW, Chung AW, van den Broek MD, Barrick TR, Charlton RA, et al. (2012) Brain
370 structure and function in chronic obstructive pulmonary disease: a multimodal cranial
371 magnetic resonance imaging study. Am J Respir Crit Care Med 186: 240-245.
372 11. Shim TS, Lee JH, Kim SY, Lim TH, Kim SJ, et al. (2001) Cerebral metabolic
373 abnormalities in COPD patients detected by localized proton magnetic resonance
374 spectroscopy. Chest 120: 1506-1513.
375 12. Oncel C, Baser S, Cam M, Akdag B, Taspinar B, et al. (2010) Peripheral neuropathy in
376 chronic obstructive pulmonary disease. COPD 7: 11-16.
377 13. Kirkil G, Tug T, Ozel E, Bulut S, Tekatas A, et al. (2007) The evaluation of cognitive
378 functions with P300 test for chronic obstructive pulmonary disease patients in attack
379 and stable period. Clin Neurol Neurosurg 109: 553-560.
380 14. Hopkinson NS, Sharshar T, Ross ET, Nickol AH, Dayer MJ, et al. (2004) Corticospinal
381 control of respiratory muscles in chronic obstructive pulmonary disease. Respir
382 Physiol Neurobiol 141: 1-12.
383 15. Mador MJ, Deniz O, Aggarwal A, Kufel TJ (2003) Quadriceps fatigability after single
384 muscle exercise in patients with chronic obstructive pulmonary disease. Am J Respir
385 Crit Care Med 168: 102-108.
386 16. Seymour JM, Ward K, Raffique A, Steier JS, Sidhu PS, et al. (2012) Quadriceps and
387 ankle dorsiflexor strength in chronic obstructive pulmonary disease. Muscle Nerve 46:
388 548-554.
389 17. Vivodtzev I, Flore P, Levy P, Wuyam B (2008) Voluntary activation during knee
390 extensions in severely deconditioned patients with chronic obstructive pulmonary
391 disease: benefit of endurance training. Muscle Nerve 37: 27-35.
392 18. Herbert RD, Gandevia SC (1999) Twitch interpolation in human muscles: mechanisms
393 and implications for measurement of voluntary activation. J Neurophysiol 82: 2271-
394 2283.
395 19. van Duinen H, Renken R, Maurits NM, Zijdewind I (2008) Relation between muscle and
396 brain activity during isometric contractions of the first dorsal interosseus muscle. Hum
397 Brain Mapp 29: 281-299.
398 20. Derosiere G, Perrey S (2012) Relationship between submaximal handgrip muscle force
399 and NIRS-measured motor cortical activation. Adv Exp Med Biol 737: 269-274.
400 21. Strangman G, Culver JP, Thompson JH, Boas DA (2002) A quantitative comparison of
401 simultaneous BOLD fMRI and NIRS recordings during functional brain activation.
402 Neuroimage 17: 719-731.

403 22. Sato H, Yahata N, Funane T, Takizawa R, Katura T, et al. (2013) A NIRS-fMRI
404 investigation of prefrontal cortex activity during a working memory task. Neuroimage
405 83: 158-173.
406 23. Mehagnoul-Schipper DJ, van der Kallen BF, Colier WN, van der Sluijs MC, van Erning
407 LJ, et al. (2002) Simultaneous measurements of cerebral oxygenation changes during
408 brain activation by near-infrared spectroscopy and functional magnetic resonance
409 imaging in healthy young and elderly subjects. Hum Brain Mapp 16: 14-23.
410 24. Higashimoto Y, Honda N, Yamagata T, Matsuoka T, Maeda K, et al. (2011) Activation of
411 the prefrontal cortex is associated with exertional dyspnea in chronic obstructive
412 pulmonary disease. Respiration 82: 492-500.
413 25. Lin PY, Chen JJ, Lin SI (2013) The cortical control of cycling exercise in stroke patients:
414 an fNIRS study. Hum Brain Mapp 34: 2381-2390.
415 26. Mehta RK, Shortz AE (2013) Obesity-related differences in neural correlates of force
416 control. Eur J Appl Physiol.
417 27. Perrey S (2008) Non-invasive NIR spectroscopy of human brain function during exercise.
418 Methods 45: 289-299.
419 28. Ekkekakis P (2009) Illuminating the black box: investigating prefrontal cortical
420 hemodynamics during exercise with near-infrared spectroscopy. J Sport Exerc Psychol
421 31: 505-553.
422 29. Fox PT, Raichle ME, Mintun MA, Dence C (1988) Nonoxidative glucose consumption
423 during focal physiologic neural activity. Science 241: 462-464.
424 30. Colier WN, Quaresima V, Oeseburg B, Ferrari M (1999) Human motor-cortex
425 oxygenation changes induced by cyclic coupled movements of hand and foot. Exp
426 Brain Res 129: 457-461.
427 31. (1994) Guideline thirteen: guidelines for standard electrode position nomenclature.
428 American Electroencephalographic Society. J Clin Neurophysiol 11: 111-113.
429 32. Duncan A, Meek JH, Clemence M, Elwell CE, Fallon P, et al. (1996) Measurement of
430 cranial optical path length as a function of age using phase resolved near infrared
431 spectroscopy. Pediatr Res 39: 889-894.
432 33. Chow JW, Stokic DS (2011) Force control of quadriceps muscle is bilaterally impaired in
433 subacute stroke. J Appl Physiol (1985) 111: 1290-1295.
434 34. Missenard O, Mottet D, Perrey S (2008) Muscular fatigue increases signal-dependent
435 noise during isometric force production. Neurosci Lett 437: 154-157.
436 35. Minagawa-Kawai Y, van der Lely H, Ramus F, Sato Y, Mazuka R, et al. (2011) Optical
437 brain imaging reveals general auditory and language-specific processing in early
438 infant development. Cereb Cortex 21: 254-261.
439 36. Voorrips LE, Ravelli AC, Dongelmans PC, Deurenberg P, Van Staveren WA (1991) A
440 physical activity questionnaire for the elderly. Med Sci Sports Exerc 23: 974-979.
441 37. Mador MJ, Bozkanat E (2001) Skeletal muscle dysfunction in chronic obstructive
442 pulmonary disease. Respir Res 2: 216-224.
443 38. Yildiz S, Kaya I, Cece H, Gencer M, Ziylan Z, et al. (2012) Impact of COPD exacerbation
444 on cerebral blood flow. Clin Imaging 36: 185-190.
445 39. Albayrak R, Fidan F, Unlu M, Sezer M, Degirmenci B, et al. (2006) Extracranial carotid
446 Doppler ultrasound evaluation of cerebral blood flow volume in COPD patients.
447 Respir Med 100: 1826-1833.
448 40. Nishimura Y, Onoe H, Morichika Y, Tsukada H, Isa T (2007) Activation of parieto-
449 frontal stream during reaching and grasping studied by positron emission tomography
450 in monkeys. Neurosci Res 59: 243-250.

451 41. Manto M, Bower JM, Conforto AB, Delgado-Garcia JM, da Guarda SN, et al. (2012)
452 Consensus paper: roles of the cerebellum in motor control--the diversity of ideas on
453 cerebellar involvement in movement. Cerebellum 11: 457-487.
454 42. Paulin MG (1993) The role of the cerebellum in motor control and perception. Brain
455 Behav Evol 41: 39-50.
456 43. Dodd JW, Getov SV, Jones PW (2010) Cognitive function in COPD. Eur Respir J 35:
457 913-922.
458 44. Kramer AF, Erickson KI (2007) Capitalizing on cortical plasticity: influence of physical
459 activity on cognition and brain function. Trends Cogn Sci 11: 342-348.

460 **Figures**

461

462 **Figure 1.** Experimental Design. MVC: Maximal Voluntary Contraction, SVC: Submaximal

463 Voluntary Contraction.

464



465

Figure 2. Measurement of cortical activity by functional near-infrared spectroscopy (fNIRS). a) fNIRS optode placement. Three receivers (black circles) and seven emitters (white circles) were set over the scalp, resulting in 9 measured channels. The crosses represent the reference points used to target primary sensory (CP_3 - CP_1), primary motor (C_3 - C_1), premotor (FC_1 - FC_3) and prefrontal cortical areas (FP_1) according to the modified international EEG 10-10 system. I_z: Inion, N_z: Nasion.

b) Example of a functional near-infrared spectrospcopy oxyhemoglobin signal (fNIRS-HbO) during a maximal voluntary contraction in one subject. Hatched area represents the area under the curve of HbO (as index of neural activity).



478 **Figure 3.** HbO changes during maximal voluntary contractions over primary motor (M1),
479 primary sensory (S1), premotor (PMC) and prefrontal (PFC) cortex areas. * $p < 0.05$ and ** p
480 < 0.01 significantly different from controls.



481

Figure 4. Performed torque versus target torque during submaximal voluntary contractions at 10, 30 and 50% of maximal quadriceps torque (Q_{MVC}). NS: Non-significant difference between target and performed torque.



Figure 5. HbO changes during submaximal quadriceps contractions as a function of % of maximal quadriceps torque (Q_{MVC}) over primary motor (M1), primary sensory (S1), premotor (PMC) and prefrontal (PFC) cortex areas. Values in parenthesis on the x axis indicate the mean torque performed at the given % of maximal quadriceps torque. Significant differences from rest: † $p < 0.05$ †† $p < 0.01$ and ††† $p < 0.001$. Significant differences between controls and patients: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.



496 **Figure 6.** HbO changes over M1 as a function of absolute torque value at 10 (triangular
497 shape), 30 (circular shape) and 50% (square shape) of the maximal voluntary torque.



498

499 **Table 1. Characteristics of the subjects included in the study**

	Control (n=15)	COPD (n=15)	p-value
Gender M/F	10/5	10/5	
Age yrs	61 (2.9)	62.8 (2.5)	NS (0.64)
Weight kg	75.8 (3.3)	72.8 (4.2)	NS (0.57)
BMI $kg.m^{-2}$	25.8 (1)	25.3 (1.3)	NS (0.76)
FEV_1 L	3.1 (0.2)	1.5 (0.2)	<0.001
FEV_1 % pred	104.5 (3)	54.1 (3.6)	<0.001
FEV_1/FVC	73.1 (1.1)	49.7 (2.4)	<0.001
FFM kg	55.3 (3)	53.9 (3)	NS (0.73)
FFMI $kg.m^{-2}$	18.6 (0.5)	18.8 (0.7)	NS (0.92)
Voorrips AU	7.4 (1.25)	6.5 (1.35)	NS (0.64)
PaO_2 mmHg		72.9 (2.8)	
$PaCO_2$ mmHg		37.4 (1.4)	

500 BMI: Body Mass Index, FEV_1: Force Expiratory Volume in 1 s, FVC: Force Vital Capacity, FFM: Fat-Free
501 Mass, FFMI: Fat-Free Mass Index. NS: no significant difference between controls and COPD patients.
502 Values are mean (SE).

503